Loading...

Compumedics

ASX:CMP
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CMP
ASX
A$83M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Compumedics Limited researches, develops, manufactures, sells, and distributes medical equipment in Australia, New Zealand, the United States, Europe, the Middle East, Africa, and Asia. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
  • Compumedics has significant price volatility in the past 3 months.
CMP Share Price and Events
7 Day Returns
9.3%
ASX:CMP
3.4%
AU Medical Equipment
0.7%
AU Market
1 Year Returns
13.3%
ASX:CMP
-3.4%
AU Medical Equipment
4.7%
AU Market
CMP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Compumedics (CMP) 9.3% 42.4% 32.4% 13.3% 14.6% 327.3%
AU Medical Equipment 3.4% 0.5% 0.7% -3.4% 39.3% 105.3%
AU Market 0.7% 1.1% 6.5% 4.7% 17.5% 4.9%
1 Year Return vs Industry and Market
  • CMP outperformed the Medical Equipment industry which returned -3.4% over the past year.
  • CMP outperformed the Market in Australia which returned 4.7% over the past year.
Price Volatility
CMP
Industry
5yr Volatility vs Market

CMP Value

 Is Compumedics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Compumedics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Compumedics.

ASX:CMP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:CMP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.929 (1 + (1- 30%) (2.19%))
0.962
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.962 * 5.96%)
8.04%

Discounted Cash Flow Calculation for ASX:CMP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Compumedics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:CMP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 8.04%)
2019 1.60 Analyst x1 1.48
2020 8.90 Analyst x1 7.62
2021 11.80 Analyst x1 9.36
2022 21.30 Analyst x1 15.63
2023 28.30 Analyst x1 19.22
2024 34.09 Est @ 20.46% 21.43
2025 39.21 Est @ 15.02% 22.82
2026 43.61 Est @ 11.21% 23.48
2027 47.33 Est @ 8.54% 23.59
2028 50.49 Est @ 6.67% 23.29
Present value of next 10 years cash flows A$167.93
ASX:CMP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$50.49 × (1 + 2.31%) ÷ (8.04% – 2.31%)
A$901.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$901.22 ÷ (1 + 8.04%)10
A$415.76
ASX:CMP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$167.93 + A$415.76
A$583.69
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$583.69 / 177.16
A$3.29
ASX:CMP Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$3.29
Current discount Discount to share price of A$0.47
= -1 x (A$0.47 - A$3.29) / A$3.29
85.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Compumedics is available for.
Intrinsic value
>50%
Share price is A$0.47 vs Future cash flow value of A$3.29
Current Discount Checks
For Compumedics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Compumedics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Compumedics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Compumedics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Compumedics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CMP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.02
ASX:CMP Share Price ** ASX (2019-04-18) in AUD A$0.47
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Compumedics.

ASX:CMP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CMP Share Price ÷ EPS (both in AUD)

= 0.47 ÷ 0.02

28.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Compumedics is good value based on earnings compared to the AU Medical Equipment industry average.
  • Compumedics is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Compumedics's expected growth come at a high price?
Raw Data
ASX:CMP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 28.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
46%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

ASX:CMP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 28.34x ÷ 46%

0.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Compumedics is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Compumedics's assets?
Raw Data
ASX:CMP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.14
ASX:CMP Share Price * ASX (2019-04-18) in AUD A$0.47
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.73x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:CMP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CMP Share Price ÷ Book Value per Share (both in AUD)

= 0.47 ÷ 0.14

3.44x

* Primary Listing of Compumedics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Compumedics is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Compumedics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Compumedics has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CMP Future Performance

 How is Compumedics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
46%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Compumedics expected to grow at an attractive rate?
  • Compumedics's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Compumedics's earnings growth is expected to exceed the Australia market average.
  • Compumedics's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:CMP Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:CMP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 46%
ASX:CMP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 28.4%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CMP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CMP Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 145 31 35 1
2022-06-30 122 24 28 1
2021-06-30 97 14 19 1
2020-06-30 70 12 10 1
2019-06-30 43 4 4 1
ASX:CMP Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 40 3 3
2018-09-30 38 2 3
2018-06-30 37 1 3
2018-03-31 36 0 2
2017-12-31 34 -1 2
2017-09-30 34 0 2
2017-06-30 34 1 1
2017-03-31 35 2 1
2016-12-31 36 4 2
2016-09-30 37 3 2
2016-06-30 38 2 3
2016-03-31 36 2 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Compumedics's earnings are expected to grow significantly at over 20% yearly.
  • Compumedics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CMP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Compumedics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CMP Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.20 0.20 0.20 1.00
2022-06-30 0.16 0.16 0.16 1.00
2021-06-30 0.11 0.11 0.11 1.00
2020-06-30 0.05 0.05 0.05 1.00
2019-06-30 0.02 0.02 0.02 1.00
ASX:CMP Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.02
2018-09-30 0.02
2018-06-30 0.02
2018-03-31 0.01
2017-12-31 0.01
2017-09-30 0.01
2017-06-30 0.01
2017-03-31 0.01
2016-12-31 0.01
2016-09-30 0.01
2016-06-30 0.02
2016-03-31 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Compumedics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Compumedics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Compumedics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CMP Past Performance

  How has Compumedics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Compumedics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Compumedics's year on year earnings growth rate has been positive over the past 5 years.
  • Compumedics's 1-year earnings growth exceeds its 5-year average (71.7% vs 19%)
  • Compumedics's earnings growth has exceeded the AU Medical Equipment industry average in the past year (71.7% vs 62.3%).
Earnings and Revenue History
Compumedics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Compumedics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CMP Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 39.61 2.95 13.60 5.70
2018-09-30 38.31 2.87 13.30 5.40
2018-06-30 37.00 2.78 13.00 5.11
2018-03-31 35.66 2.25 13.16 5.08
2017-12-31 34.33 1.72 13.33 5.05
2017-09-30 34.37 1.51 12.93 5.47
2017-06-30 34.42 1.31 12.53 5.88
2017-03-31 35.40 1.47 12.10 5.96
2016-12-31 36.38 1.64 11.66 6.04
2016-09-30 36.96 2.45 11.68 5.89
2016-06-30 37.54 3.27 11.70 5.75
2016-03-31 36.38 3.10 11.63 5.11
2015-12-31 35.22 2.93 11.57 4.47
2015-09-30 34.36 2.45 11.47 4.61
2015-06-30 33.50 1.97 11.37 4.76
2015-03-31 32.75 1.69 11.06 5.27
2014-12-31 32.00 1.41 10.76 5.79
2014-09-30 31.42 1.16 10.60 5.47
2014-06-30 30.84 0.91 10.45 5.16
2014-03-31 29.65 0.29 10.45 5.02
2013-12-31 28.45 -0.32 10.44 4.88
2013-09-30 27.80 -0.90 10.41 4.99
2013-06-30 27.15 -1.49 10.38 5.09
2013-03-31 26.73 -2.62 10.29 5.18
2012-12-31 26.31 -3.75 10.20 5.26
2012-09-30 27.11 -3.29 10.62 4.95
2012-06-30 27.92 -2.83 11.04 4.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Compumedics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Compumedics used its assets less efficiently than the AU Medical Equipment industry average last year based on Return on Assets.
  • Compumedics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Compumedics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Compumedics has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CMP Health

 How is Compumedics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Compumedics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Compumedics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Compumedics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Compumedics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 15.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Compumedics Company Filings, last reported 3 months ago.

ASX:CMP Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 24.20 1.82 4.29
2018-09-30 24.20 1.82 4.29
2018-06-30 23.16 1.89 3.91
2018-03-31 23.16 1.89 3.91
2017-12-31 20.87 0.83 2.95
2017-09-30 20.87 0.83 2.95
2017-06-30 20.05 0.72 4.10
2017-03-31 20.05 0.72 4.10
2016-12-31 19.04 0.99 5.72
2016-09-30 19.04 0.99 5.72
2016-06-30 14.60 2.58 3.07
2016-03-31 14.60 2.58 3.07
2015-12-31 13.27 1.92 1.67
2015-09-30 13.27 1.92 1.67
2015-06-30 11.27 2.00 2.23
2015-03-31 11.27 2.00 2.23
2014-12-31 10.33 2.56 1.65
2014-09-30 10.33 2.56 1.65
2014-06-30 9.16 2.02 1.05
2014-03-31 9.16 2.02 1.05
2013-12-31 8.83 2.02 1.29
2013-09-30 8.83 2.02 1.29
2013-06-30 8.35 2.34 1.29
2013-03-31 8.35 2.34 1.29
2012-12-31 8.43 2.36 1.65
2012-09-30 8.43 2.36 1.65
2012-06-30 9.22 2.08 1.10
  • Compumedics's level of debt (7.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (22.9% vs 7.5% today).
  • Debt is well covered by operating cash flow (149.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 16.9x coverage).
X
Financial health checks
We assess Compumedics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Compumedics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CMP Dividends

 What is Compumedics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Compumedics dividends. Estimated to be 5.57% next year.
If you bought A$2,000 of Compumedics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Compumedics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Compumedics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CMP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:CMP Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30 0.05 1.00
2022-06-30 0.04 1.00
2021-06-30 0.03 1.00
2020-06-30 0.01 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Compumedics has not reported any payouts.
  • Unable to verify if Compumedics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Compumedics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Compumedics has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4x coverage).
X
Income/ dividend checks
We assess Compumedics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Compumedics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Compumedics has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CMP Management

 What is the CEO of Compumedics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Burton
COMPENSATION A$249,967
AGE 59
CEO Bio

Dr. David Burton, Ph.D. founded Compumedics Ltd. in 1987 and serves as its Executive Chairman and Chief Executive Officer. Dr. Burton serves as Executive Chairman and Chief Executive Officer of Compumedics USA, LLC. He started his career at the Bureau of Meteorology, where he studied radar techniques and electronic equipment. He founded Linear Transfer Pty Ltd., which designed, manufactured and marketed high fidelity recording and sound equipment. He has a background in engineering, which includes the design and project management of Compumedics' first laboratory and portable sleep systems. Dr. Burton serves as Member of Medical Advisory Board of Compumedics Limited. He serves as a Director of Intellirad Pty Ltd., D&DJ Burton Holdings Pty Ltd and Electro Molecular Pty Ltd. He serves as a member of the Victorian Government's Council for Knowledge, Innovation, Science and Engineering. He serves as a former member of the Council for Knowledge, Innovation, Science and Engineering (KISE) - being the Victorian Government's key advisory body on issues and policies focusing on science and innovation. He has authored fourteen publications and patents that form part of Compumedics Ltd.'s key intellectual property. He has a demonstrated track record in all aspects of running a technology business, including research and development, technical and business management, project management, intellectual property management and sales and marketing. Dr. Burton was presented the Clunies Ross National Science and Technology Award in 2002 for his development of innovative sleep monitoring technology. He has been awarded 24 awards for design, innovation, business and exports including the Australian Exporter of the Year in 1998 and Small Business of the Year in 1999. He was awarded the 2003 Centenary Medal by the Prime Minister and Governor General of Australia for outstanding contribution to science and technology, particularly public science policy. In 2003, he was awarded the Ernst & Young Victorian Entrepreneur of the Year award for technology, communications, E-commerce and life sciences. Dr. Burton has as an Associate Diploma in Electronics Engineering from the Royal Melbourne Institute of Technology and has Phd (Eng. Sc.) in the area of medical technology innovation at Monash University.

CEO Compensation
  • David's compensation has been consistent with company performance over the past year.
  • David's remuneration is about average for companies of similar size in Australia.
Management Team

David Burton

TITLE
Founder
COMPENSATION
A$250K
AGE
59

David Lawson

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
A$283K
AGE
53

Warwick Freeman

TITLE
Chief Technology Officer
COMPENSATION
A$283K

Kerry Hubick

TITLE
Legal Counsel and Trademark
COMPENSATION
A$81K

Christoph Witte

TITLE
General Managing of Director DWL Compumedics Germany GmbH
COMPENSATION
A$339K

Curtis Ponton

TITLE
Chief Scientist of Neuroscan & VP
COMPENSATION
A$189K

Paul Spooner

TITLE
Business Director of EMEA
COMPENSATION
A$233K
Board of Directors Tenure

Average tenure and age of the Compumedics board of directors in years:

2.3
Average Tenure
59
Average Age
  • The average tenure for the Compumedics board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Burton

TITLE
Founder
COMPENSATION
A$250K
AGE
59

David Lawson

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
A$283K
AGE
53
TENURE
5.5 yrs

Alan Anderson

TITLE
Non-Executive Director
COMPENSATION
A$40K
AGE
62

Ian Colrain

TITLE
Member of Medical Advisory Board
TENURE
2.3 yrs

Patrice Bourgin

TITLE
Member of Medical Advisory Board
TENURE
2.3 yrs

John Ebersole

TITLE
Member of Medical Advisory Board
TENURE
2.3 yrs

Tucson Dunn

TITLE
Non-Executive Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Compumedics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Compumedics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CMP News

Simply Wall St News

Is Compumedics Limited's (ASX:CMP) CEO Salary Justified?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does David Burton's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below AU$283m

Simply Wall St -

Do Insiders Own Lots Of Shares In Compumedics Limited (ASX:CMP)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Compumedics is a smaller company with a market capitalization of AU$61m, so it may still be flying under the radar of many institutional investors. … institutional investors have not yet purchased much of the company

Simply Wall St -

Is Compumedics Limited's (ASX:CMP) ROE Of 12% Impressive?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Compumedics has a return on equity of 12% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Compumedics Limited (ASX:CMP) Is Employing Capital Very Effectively

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Understanding Return On Capital Employed (ROCE). … How Do You Calculate Return On Capital Employed

Simply Wall St -

Looking At Compumedics Limited (ASX:CMP) From All Angles

Attractive stocks have exceptional fundamentals. … In the case of Compumedics Limited (ASX:CMP), there's … financially-sound

Simply Wall St -

Is Compumedics Limited's (ASX:CMP) High P/E Ratio A Problem For Investors?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Compumedics has a price to earnings ratio of 24.18, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

What Kind Of Shareholder Appears On The Compumedics Limited's (ASX:CMP) Shareholder Register?

If you want to know who really controls Compumedics Limited (ASX:CMP), then you'll have to look at the makeup of its share registry. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of AU$68m, Compumedics is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Compumedics Limited (ASX:CMP)'s Return on Capital

and looking to gauge the potential return on investment in Compumedics Limited (ASX:CMP). … Therefore, looking at how efficiently Compumedics is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Does Compumedics Limited's (ASX:CMP) PE Ratio Warrant A Sell?

Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind. … I will break down what the P/E ratio is, how to interpret it and what to watch out for … Demystifying the P/E ratio

Simply Wall St -

Who Are The Major Shareholders Of Compumedics Limited (ASX:CMP)?

Today, I will be analyzing Compumedics Limited’s (ASX:CMP) recent ownership structure, an important but not-so-popular subject among individual investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Therefore, it is beneficial for us to examine CMP's ownership structure in more detail.

Simply Wall St -

CMP Company Info

Description

Compumedics Limited researches, develops, manufactures, sells, and distributes medical equipment in Australia, New Zealand, the United States, Europe, the Middle East, Africa, and Asia. It provides sleep diagnostics products, including Grael 4K PSG/EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; ProFusion neXus 360, a Web-based patient data and lab management system that provides integrated hardware and software solutions for both sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was founded in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.

Details
Name: Compumedics Limited
CMP
Exchange: ASX
Founded: 1987
A$83,266,585
177,162,948
Website: http://www.compumedics.com.au
Address: Compumedics Limited
30-40 Flockhart Street,
Abbotsford,
Victoria, 3067,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CMP Ordinary Shares Australian Securities Exchange AU AUD 22. Dec 2000
CHIA CMP Ordinary Shares Chi-X Australia AU AUD 22. Dec 2000
Number of employees
Current staff
Staff numbers
0
Compumedics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 10:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.